Hans Lennart Rudolf Wigzell, a director at $SRPT ($SRPT), sold 10,500 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 31.5%...
Piper reduced Sarepta’s price target to $182 from $200, highlighting the partnership’s near-term financial impact.
The global licensing deal includes $500 million in cash and $325 million in equity, at a 35% premium upon closing.
SRPT earnings call for the period ending September 30, 2024.
Sarepta Therapeutics: Q3 Earnings Snapshot
These innovative drugmakers have potential catalysts ahead.
These two could become direct competitors relatively soon.
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2024 $80 Call had some of the highest implied...
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.